VANCOUVER, June 12 /CNW/ - Radcliffe Foundation (the "Purchaser") reports
that the Purchaser has acquired ownership of 2,000,000 common shares of
Prescient Neuropharma Inc. (the "Issuer").
Upon completion of the acquisition, the Purchaser holds 7,100,000 common
shares of the Issuer, representing approximately 9.91% of the outstanding
shares of the Issuer at the time of acquisition of the shares.
The Purchaser also owns 5,100,000 common share purchase warrants of the
Issuer. Assuming exercise of all of the warrants, the Purchaser would hold a
total of 12,200,000 common shares, which would represent approximately 15.93%
of the outstanding shares of the Issuer.
The transaction involved an acquisition of shares by way of a private
transaction. The securities were acquired for investment purposes. While the
Purchaser does not intend to acquire further securities of the Issuer, it may
in the future acquire or dispose of securities of the Issuer, through the
market or otherwise, as circumstances or market conditions warrant.
The TSX Venture Exchange does not accept responsibility for the adequacy
or accuracy of this News Release.
For further information:
For further information: RADCLIFFE FOUNDATION, "John Proust", Tel: (604)